Ziopharm Oncology said Friday it named John Amedio Vice President, Manufacturing & Process Development.
Amedio joins Ziopharm from Epix Pharmaceuticals, where he was most recently Executive Director, Chemical and Analytical Research & Development. He was with Sandoz Pharmaceuticals (now part of Novartis Pharmaceuticals) prior to joining EPIX.
Ziopharm said Amedio will help lead the company's evolution from small-scale production of material for early clinical trials to the large batches required for pivotal studies.
Ziopharm is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs.